Gender-affirming hormone therapy induces specific DNA methylation changes in blood.
DNA methylation
EPIC array
Epigenetics
Feminization
GAHT
Gender
Immunity
Masculinization
Transgender
Journal
Clinical epigenetics
ISSN: 1868-7083
Titre abrégé: Clin Epigenetics
Pays: Germany
ID NLM: 101516977
Informations de publication
Date de publication:
17 02 2022
17 02 2022
Historique:
received:
22
08
2021
accepted:
13
01
2022
entrez:
18
2
2022
pubmed:
19
2
2022
medline:
3
3
2022
Statut:
epublish
Résumé
DNA methylation is an epigenetic mark that is influenced by underlying genetic profile, environment, and ageing. In addition to X-linked DNA methylation, sex-specific methylation patterns are widespread across autosomal chromosomes and can be present from birth or arise over time. In individuals where gender identity and sex assigned at birth are markedly incongruent, as in the case of transgender people, feminization or masculinization may be sought through gender-affirming hormone therapy (GAHT). GAHT is a cornerstone of transgender care, yet no studies to date have investigated its effect on genome-wide methylation. We profiled genome-wide DNA methylation in blood of transgender women (n = 13) and transgender men (n = 13) before and during GAHT (6 months and 12 months into feminizing or masculinizing hormone therapy). We identified several thousand differentially methylated CpG sites (DMPs) (Δβ ≥ 0.02, unadjusted p value < 0.05) and several differentially methylated regions (DMRs) in both people undergoing feminizing and masculinizing GAHT, the vast majority of which were progressive changes over time. X chromosome and sex-specific autosomal DNA methylation patterns established in early development are largely refractory to change in association with GAHT, with only 3% affected (Δβ ≥ 0.02, unadjusted p value < 0.05). The small number of sex-specific DMPs that were affected by GAHT were those that become sex-specific during the lifetime, known as sex-and-age DMPs, including DMRs in PRR4 and VMP1 genes. The GAHT-induced changes at these sex-associated probes consistently demonstrated a shift towards the methylation signature of the GAHT-naïve opposite sex, and we observed enrichment of previously reported adolescence-associated methylation changes. We provide evidence for GAHT inducing a unique blood methylation signature in transgender people. This study advances our understanding of the complex interplay between sex hormones, sex chromosomes, and DNA methylation in the context of immunity. We highlight the need to broaden the field of 'sex-specific' immunity beyond cisgender males and cisgender females, as transgender people on GAHT exhibit a unique molecular profile.
Sections du résumé
BACKGROUND
DNA methylation is an epigenetic mark that is influenced by underlying genetic profile, environment, and ageing. In addition to X-linked DNA methylation, sex-specific methylation patterns are widespread across autosomal chromosomes and can be present from birth or arise over time. In individuals where gender identity and sex assigned at birth are markedly incongruent, as in the case of transgender people, feminization or masculinization may be sought through gender-affirming hormone therapy (GAHT). GAHT is a cornerstone of transgender care, yet no studies to date have investigated its effect on genome-wide methylation. We profiled genome-wide DNA methylation in blood of transgender women (n = 13) and transgender men (n = 13) before and during GAHT (6 months and 12 months into feminizing or masculinizing hormone therapy).
RESULTS
We identified several thousand differentially methylated CpG sites (DMPs) (Δβ ≥ 0.02, unadjusted p value < 0.05) and several differentially methylated regions (DMRs) in both people undergoing feminizing and masculinizing GAHT, the vast majority of which were progressive changes over time. X chromosome and sex-specific autosomal DNA methylation patterns established in early development are largely refractory to change in association with GAHT, with only 3% affected (Δβ ≥ 0.02, unadjusted p value < 0.05). The small number of sex-specific DMPs that were affected by GAHT were those that become sex-specific during the lifetime, known as sex-and-age DMPs, including DMRs in PRR4 and VMP1 genes. The GAHT-induced changes at these sex-associated probes consistently demonstrated a shift towards the methylation signature of the GAHT-naïve opposite sex, and we observed enrichment of previously reported adolescence-associated methylation changes.
CONCLUSION
We provide evidence for GAHT inducing a unique blood methylation signature in transgender people. This study advances our understanding of the complex interplay between sex hormones, sex chromosomes, and DNA methylation in the context of immunity. We highlight the need to broaden the field of 'sex-specific' immunity beyond cisgender males and cisgender females, as transgender people on GAHT exhibit a unique molecular profile.
Identifiants
pubmed: 35177097
doi: 10.1186/s13148-022-01236-4
pii: 10.1186/s13148-022-01236-4
pmc: PMC8851870
doi:
Substances chimiques
Hormones
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
24Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2022. The Author(s).
Références
Nat Immunol. 2018 Sep;19(9):963-972
pubmed: 30082830
Epigenetics Chromatin. 2015 Jan 27;8:6
pubmed: 25972926
Nat Immunol. 2021 Jan;22(1):2-6
pubmed: 33293712
Nat Biotechnol. 2010 May;28(5):495-501
pubmed: 20436461
J Clin Invest. 2015 Jun;125(6):2187-93
pubmed: 25915581
Biol Sex Differ. 2015 Jun 25;6:11
pubmed: 26113971
Am J Public Health. 2017 Feb;107(2):e1-e8
pubmed: 28075632
Lupus Sci Med. 2016 Dec 7;3(1):e000183
pubmed: 28074145
Transl Psychiatry. 2019 Feb 4;9(1):68
pubmed: 30718449
Nature. 2014 Jul 31;511(7511):611-5
pubmed: 25079558
Bioinformatics. 2014 May 15;30(10):1363-9
pubmed: 24478339
PLoS Pathog. 2009 Jan;5(1):e1000267
pubmed: 19180235
Lupus. 2018 Nov;27(13):2166-2169
pubmed: 30231802
J Bone Miner Res. 2018 Nov;33(11):1980-1989
pubmed: 29924424
Bioinformatics. 2011 Nov 15;27(22):3209-10
pubmed: 21976420
Lupus. 2013 Nov;22(13):1399-402
pubmed: 23897544
Pharmacol Res Perspect. 2019 Dec 06;7(6):e00541
pubmed: 31844524
Aging (Albany NY). 2020 Dec 3;12(23):24057-24080
pubmed: 33276343
Genome Biol. 2014 Dec 03;15(12):522
pubmed: 25517766
Front Mol Neurosci. 2020 Mar 31;13:42
pubmed: 32296305
Aging Cell. 2010 Dec;9(6):1098-110
pubmed: 20883525
Gastroenterology. 2019 Jun;156(8):2254-2265.e3
pubmed: 30779925
Mol Cell Endocrinol. 2009 May 25;304(1-2):8-18
pubmed: 19433243
Twin Res Hum Genet. 2015 Dec;18(6):647-61
pubmed: 26678050
Front Neurosci. 2021 Aug 19;15:701017
pubmed: 34489625
Expert Rev Clin Immunol. 2019 Jun;15(6):607-615
pubmed: 31033369
Front Immunol. 2018 Jun 12;9:1332
pubmed: 29946321
Cell. 2016 Nov 17;167(5):1354-1368.e14
pubmed: 27863248
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
Sci Rep. 2021 Apr 28;11(1):9201
pubmed: 33911141
Nat Rev Immunol. 2019 Jul;19(7):417-432
pubmed: 30918351
Oncol Lett. 2018 Apr;15(4):4669-4675
pubmed: 29541239
J Rheumatol. 2007 Sep;34(9):1938-40
pubmed: 17696264
Epigenet Insights. 2019 Aug 13;12:2516865719867090
pubmed: 31453433
BMC Psychiatry. 2021 Feb 8;21(1):81
pubmed: 33557793
Sci Rep. 2016 Aug 03;6:30664
pubmed: 27485166
EMBO Mol Med. 2019 May;11(5):
pubmed: 30979711
Genome Biol. 2016 Oct 7;17(1):208
pubmed: 27717381
N Engl J Med. 2018 Apr 05;378(14):1323-1334
pubmed: 29617578
Cell. 2016 Nov 3;167(4):1111-1124.e13
pubmed: 27814508
JMIR Res Protoc. 2021 May 19;10(5):e24100
pubmed: 34009131
Neurosci Lett. 2018 Mar 16;669:14-23
pubmed: 28063933
Nat Commun. 2018 Aug 13;9(1):3220
pubmed: 30104673
J Clin Endocrinol Metab. 2021 Mar 8;106(3):893-901
pubmed: 32810277
Nat Rev Immunol. 2016 Oct;16(10):626-38
pubmed: 27546235
Curr Psychiatry Rep. 2018 Oct 11;20(12):110
pubmed: 30306351
Gastroenterology. 2018 Oct;155(4):1079-1089.e3
pubmed: 29958857
Trends Immunol. 2014 Mar;35(3):97-104
pubmed: 24239225
Genome Med. 2019 Dec 31;12(1):1
pubmed: 31892350
BMC Bioinformatics. 2010 Nov 30;11:587
pubmed: 21118553
Bioinformatics. 2014 May 15;30(10):1431-9
pubmed: 24451622
Mol Cell. 2010 May 28;38(4):576-89
pubmed: 20513432
Clin Exp Rheumatol. 2018 Jul-Aug;36 Suppl 113(4):50-52
pubmed: 29465362
Genome Biol. 2015 Jan 30;16:25
pubmed: 25633388
Hum Reprod Update. 2005 Jul-Aug;11(4):411-23
pubmed: 15817524
Nat Commun. 2022 Feb 9;13(1):761
pubmed: 35140201
J Sex Med. 2020 Sep;17(9):1795-1806
pubmed: 32636163
Bioinformatics. 2016 Jan 15;32(2):286-8
pubmed: 26424855
Nat Commun. 2016 Nov 25;7:13507
pubmed: 27886173
Hum Mol Genet. 2015 Mar 15;24(6):1528-39
pubmed: 25381334
Cancers (Basel). 2021 Apr 14;13(8):
pubmed: 33919912
Genome Biol. 2014 Dec 03;15(12):503
pubmed: 25599564
Nat Genet. 2007 Apr;39(4):457-66
pubmed: 17334365
J Steroid Biochem Mol Biol. 2017 Sep;172:20-28
pubmed: 28539237
Clin Epigenetics. 2018 May 9;10:62
pubmed: 29760811
Genome Biol. 2018 May 29;19(1):64
pubmed: 29843789
Annu Rev Genet. 1997;31:571-610
pubmed: 9442908
Nat Rev Genet. 2012 May 29;13(7):484-92
pubmed: 22641018
Genome Biol. 2013;14(10):R115
pubmed: 24138928
Nat Commun. 2019 Sep 2;10(1):3922
pubmed: 31477727
Nat Biotechnol. 2013 Feb;31(2):142-7
pubmed: 23334450
Lupus. 2018 Feb;27(2):347-348
pubmed: 28992799
Front Immunol. 2019 Jul 30;10:1686
pubmed: 31428085
Bioinformatics. 2010 Mar 15;26(6):841-2
pubmed: 20110278
Epigenetics. 2015;10(10):943-57
pubmed: 26291385
JAMA Psychiatry. 2018 Sep 1;75(9):949-959
pubmed: 29998287
Genome Biol. 2012 Jun 15;13(6):R44
pubmed: 22703947
Front Immunol. 2021 Jan 21;11:604000
pubmed: 33584674
Curr Psychiatry Rep. 2019 Oct 19;21(11):110
pubmed: 31630247
Am J Public Health. 2013 Oct;103 Suppl 1:S93-101
pubmed: 23927517
Inflamm Bowel Dis. 2014 Oct;20(10):1784-93
pubmed: 25144570
Horm Mol Biol Clin Investig. 2015 Jun;22(3):111-7
pubmed: 26020563